SEC Company Response from TEKLA LIFE SCIENCES INVESTORS (HQL) (CIK 0000884121) (HQL) — May 8, 2020
TEKLA LIFE SCIENCES INVESTORS (HQL) (CIK 0000884121)
Date: May 8, 2020 · CIK: 0000884121 · Accession: 0001104659-20-058473
AI Filing Summary & Sentiment
File numbers found in text: 811-04889, 811-06565, 811-22955, 811-23037
Letter
Via EDGAR Division of Investment Management Office of Disclosure Review and Accounting 100 F Street, NE Washington, DC 20549 Re: Tekla Healthcare Investors (“HQH”) (811-04889), Tekla Life Sciences Investors (“HQL”) (811-06565), Tekla Healthcare Opportunities Fund (“THQ”) (811-22955) and Tekla World Healthcare Fund (“THW”) (811-23037) (HQH, HQL, THQ, and THW, together, the “Funds”) — Review of Annual Report Disclosures
Dear Mr. Long:
This letter responds to comments you provided to me in a telephonic conversation on Tuesday, April 28, 2020, with respect to your review pursuant to the Sarbanes-Oxley Act of 2002 of the annual report of the Funds relating to the fiscal year ended September 30, 2019. We have reproduced your comments below, followed by our responses.
1. Comment: In the footnotes to the financial statements, please disclose the counterparty for open option contracts written.
Response: We currently use exchange traded options and therefore do not have a counterparty to disclose. The Funds will incorporate your comment in future filings where applicable.
2. Comment: In the footnotes to the financial statements, please separately disclose on the Statement of Operations the realized gain or loss on forward foreign currency contracts.
Response: The Funds will incorporate your comment in future filings.
3. Comment: On the N-2, Item 4.3., loans outstanding should be considered senior securities on the financial highlights and therefore additional disclosures such as amount outstanding and asset coverage should be shown going forward for each year presented.
Response: The Funds will incorporate your comment in future filings.
We will endeavor to incorporate the applicable comments discussed above as soon as reasonably practicable.
May 8, 2020
Page 2
Very truly yours,
Laura Woodward,
Show Raw Text
CORRESP
1
filename1.htm
Tekla Healthcare Investors
Tekla Life Sciences Investors
100 Federal Street, 19th Floor
Tekla Healthcare Opportunities Fund
Boston, Massachusetts 02110
Tekla World Healthcare Fund
Tel: (617) 772-8500
May 8, 2020
Via EDGAR
Jeff Long
U.S. Securities and Exchange Commission
Division of Investment Management
Office of Disclosure Review and Accounting
100 F Street, NE
Washington, DC 20549
Re: Tekla
Healthcare Investors (“HQH”) (811-04889), Tekla Life Sciences Investors (“HQL”) (811-06565), Tekla Healthcare
Opportunities Fund (“THQ”) (811-22955) and Tekla World Healthcare Fund (“THW”) (811-23037) (HQH, HQL, THQ,
and THW, together, the “Funds”) — Review of Annual Report Disclosures
Dear Mr. Long:
This letter responds to comments you provided
to me in a telephonic conversation on Tuesday, April 28, 2020, with respect to your review pursuant to the Sarbanes-Oxley
Act of 2002 of the annual report of the Funds relating to the fiscal year ended September 30, 2019. We have reproduced your
comments below, followed by our responses.
1. Comment: In the footnotes to the financial statements, please disclose the counterparty
for open option contracts written.
Response: We
currently use exchange traded options and therefore do not have a counterparty to disclose. The Funds will incorporate your comment
in future filings where applicable.
2. Comment: In the footnotes to the financial statements, please separately disclose
on the Statement of Operations the realized gain or loss on forward foreign currency contracts.
Response: The
Funds will incorporate your comment in future filings.
3. Comment: On the N-2, Item 4.3., loans outstanding should be considered
senior securities on the financial highlights and therefore additional disclosures such as amount outstanding and asset coverage
should be shown going forward for each year presented.
Response: The
Funds will incorporate your comment in future filings.
We will endeavor to incorporate the applicable
comments discussed above as soon as reasonably practicable.
May 8, 2020
Page 2
Very truly yours,
Laura Woodward,
Chief Compliance Officer, Secretary and Treasurer
cc: Daniel
R. Omstead, Ph.D.
Christopher P. Harvey
Kaitlin McGrath